Two $175 million deals, two opposite first days
Last week produced exactly two IPO pricings on US exchanges, and they raised the same amount of money. According to Renaissance Capital's weekly recap, Windward Bio Group (WWB), a Swiss biotech, and vVardis (VVVV), a Swiss maker of a cavity treatment, each sold $175 million of stock. Their first trading days could hardly have been more different.
Windward priced at $17 per share, the midpoint of its $16 to $18 range, per its 424B4 prospectus. Renaissance puts the first-day return at 67.6%, a figure Briefs.co also reports. Reuters, via Yahoo Finance, said the stock opened at $18.35 on November 13, a valuation of about $1.07 billion at that open.
vVardis went the other way. Renaissance says it offered more shares than originally planned but priced below its range, 20% under the midpoint, for a market cap of about $1.1 billion. Its first-day return was negative 8%, and it was still down 8% as of the November 13 reference point in Renaissance's table. A third issuer, the biotech Rezera (RZRA), postponed its offering.
The lesson is not that biotech works and consumer health does not. It is that the market is paying for specific things and discounting the rest. Below, what Windward had that vVardis lacked, and what to watch in the one big deal that just entered the pipeline.
What Windward's structure shows
Start with the cap table around the deal. Windward did not simply sell 10,294,117 shares at $17 and hope. According to the prospectus, a concurrent private placement to Sanofi (SNY) brought in another $50.0 million through 1,532,691 common shares and pre-funded warrants over 1,408,485 more. Briefs.co adds that the combined raise was about $225 million. Reuters reported the same Sanofi commitment.
For issuers, a strategic investor taking a defined slice alongside the public offering does two jobs. It sets a visible floor of informed demand before the book closes, and it lets the company report a larger total raise than the public tranche alone. Windward's net proceeds were about $203.8 million, rising to about $228.0 million if underwriters exercise their full 1,544,117-share option, according to the prospectus. The underwriters were Jefferies, TD Cowen, Piper Sandler and UBS.
Then look at runway. The prospectus reports $207.3 million of cash and marketable securities at June 30, 2026, and says that with the offering proceeds the company expects to fund operations into the first half of 2029. That is the same window in which the lead program's key data arrive. The prospectus says topline results from the POLARIS-1 Phase 3 trial are expected in the first half of 2029, with Phase 2 results in the first half of 2027 and the COPD study's topline in the second half of 2027. Investors seem to have rewarded a plan where cash and catalysts line up, and punished less. Notice also how thin the cushion is: runway ending as the pivotal data land leaves little room for a delay.
The use-of-proceeds table is equally specific. About $217.5 million to $227.5 million is earmarked for the lead antibody, WIN378, and its trials. Roughly $80 million to $85 million goes to the second antibody, WIN027, and $5 million to $10 million to bispecific work. A buyer can trace nearly every dollar to a milestone. Founders drafting their own use-of-proceeds section can borrow that discipline.
Reuters also noted that biotech has stood out while the broader IPO market contends with an AI-driven tech selloff and high interest rates, and that more than half a dozen biotechs have listed in New York since September. It quoted Jeff Zell of IPO Boutique saying the sector is sometimes not truly affected by the broader market. That is one analyst's view, not a law. But it matches what the two Swiss deals show: sector-specific demand can carry a deal while generalist demand is soft.
vVardis: more shares, lower price
The vVardis book looks like the mirror image. Renaissance notes that the company is fast growing but expects to remain unprofitable in the near term, and that its US product, Curodont Repair Fluoride Plus, is sold as an over-the-counter drug under an FDA monograph and generates the vast majority of revenue. Upsizing the share count while cutting the price is a common way to protect proceeds when demand is thinner than hoped. It protects the dollar raise, but it costs dilution and usually sets a weak tone for aftermarket trading.
For issuers, the practical point is about trade-offs. A company that must hit a dollar target will often accept a lower price and more shares. A company with more runway can decline, as Rezera did by postponing. Neither choice is wrong, but both should be decided before the roadshow, not during it.
The next big test: a carve-out
The most significant filing of the week was not a pricing at all. American Barrick Gold (ABGC) filed its S-1 on November 10, according to the SEC document, proposing an NYSE listing under that symbol. Investing.com reports that it is a spin-off of Barrick Mining's North American gold assets, with Goldman Sachs (GS), BofA Securities, Citigroup and RBC Capital Markets among the underwriters.
The filing says American Barrick would operate the Nevada Gold Mines complex and own a 61.5% interest in it, with Newmont (NEM) holding the rest. Net proceeds are expected to go to Barrick, which says it intends to return them to shareholders. That makes this a seller-side liquidity event rather than a capital raise for the new company. The share count and price range have not been set, and the registration statement is not yet effective. Renaissance's own estimate puts the deal size at about $6 billion, but treat that as an estimate until terms appear.
If it prices, a deal of that scale would dwarf the $175 million transactions above and would test a different pool of capital than the biotech buyers did. Watch for the amended filing with the price range, how much of the company is floated, and whether the technical-report disclosures draw SEC comments that slow the schedule.
What to take from the week
First, pricing at the midpoint and trading up is not the same as raising at a high valuation. Windward's pop is, in one sense, money left on the table by the company, even as it signals strong demand for its next financing.
Second, a strategic cornerstone like Sanofi's can anchor a deal in a choppy market, though it brings expectations and sometimes governance rights, so read the terms.
Third, the window is open for specific stories only. Two issuers of identical size, pricing into the same market in the same week, got opposite outcomes. Make your own case concrete: milestones, runway and a use of proceeds an investor can check.
Nothing here is investment advice. First-day moves can reverse, and the figures above come from the filings and reports linked.
Sources
- Renaissance Capital: US IPO Weekly Recap, week of Nov. 9, 2026
- Reuters via Yahoo Finance: Novo Holdings-backed Windward Bio valued at $1 billion as shares rise in Nasdaq debut
- Windward Bio Group AG, Form 424B4 prospectus (Nov. 12, 2026)
- Briefs.co: Windward Bio IPO Soars 68% in Nasdaq Debut
- American Barrick Gold Corp, Form S-1 (filed Nov. 10, 2026)
- Investing.com: Barrick files S-1 for American Barrick Gold IPO on NYSE